GLP-1 Cost by State in 2026: Medicaid Coverage, Mandates and What You Actually Pay
What a GLP-1 costs depends less on which pharmacy you use than on which state you live in and what your plan is. Medicaid coverage for obesity indications is a state-by-state decision, commercial plans frequently exclude weight-loss drugs entirely, and Medicare is barred from the manufacturer savings card by federal law. The cash routes below apply everywhere; the coverage routes do not.
Why the state matters at all
Three separate systems produce three different answers, and only one of them is national.
| Layer | Who decides | Varies by state? |
|---|---|---|
| Medicaid coverage for obesity | Each state's Medicaid programme | Yes — substantially |
| Commercial plan formulary | Your employer and its PBM | Yes, but by employer not state |
| Medicare Part D | Federal | No |
| Manufacturer savings offer | Manufacturer; barred for government beneficiaries | No |
| Manufacturer self-pay price | Manufacturer | No — same everywhere |
| Telehealth availability | State licensure of the prescriber | Yes |
Only the bottom two rows are the same in every state, which is why cash pricing is the one comparison that travels.
What the cash routes cost, and they are the same in every state
Manufacturer self-pay figures read on the published price guide, 4 August 2026. These do not change by state.
Telehealth and state licensure
A telehealth prescriber must be licensed in your state, not theirs. That is why provider coverage maps exist and why a programme available to a neighbour may not be available to you. It also means a provider claiming nationwide availability is claiming a licensed prescriber in fifty jurisdictions, which is worth verifying rather than assuming.
The five questions that settle your actual price
- Is the drug on my plan's formulary, and at what tier? One call. It decides more than every comparison table combined.
- Covered for obesity, or only for diabetes? These are different formulary entries.
- Am I a government beneficiary? Medicare and Medicaid enrolment bars the manufacturer savings card by federal law.
- Does my state's Medicaid programme cover the obesity indication? A state-level question with a state-level answer.
- What is the price at a maintenance dose? Not the advertised starter figure.
If the answer is no coverage
That is a purchasing decision made by an employer or a state programme, not a clinical judgement about you, and appeals rarely reverse it. The tell is the wording: "not medically necessary" is a clinical position you can answer with documentation; "benefit not covered under your plan" is a contract term you cannot.
At that point the national cash routes above are the comparison, and an approved oral tablet at $149 for starter doses has changed that arithmetic more in eighteen months than any state policy has.
The three coverage situations, and what each actually costs
| Situation | Monthly | Why |
|---|---|---|
| Commercial plan covers the drug | $25 | Savings offer reduces an existing copay, capped at $100/month saved |
| Commercial plan excludes weight-loss drugs | $149–$349 | Cash routes; a purchasing decision, not a clinical one |
| Medicare or Medicaid | $50 via the Bridge, or cash | Savings card barred by federal law |
| Medicaid, obesity indication covered | Varies by state | A state-level policy decision |
| Medicaid, diabetes indication only | Covered for diabetes only | Same drug, different formulary entry |
| Uninsured | $149–$349 | Manufacturer self-pay, national pricing |
Only the state Medicaid rows vary geographically. Everything else is national.
Why "cheapest in my state" is usually the wrong search
Cash pricing from the manufacturer is national. A telehealth provider's price does not change because you crossed a border. What changes is whether a prescriber is licensed where you are, and what your state's Medicaid programme decided about the obesity indication.
So the productive version of the question is not "what does it cost in my state" but "does my plan cover it, and if not, which national cash route is cheapest at a maintenance dose". The second question has a stable answer; the first mostly does not.
What this page does not settle
- Your specific plan's formulary. Employers buy different benefit packages within the same state, so two neighbours can have opposite answers.
- Current Medicaid policy in any named state. These change, sometimes mid-year, and a page listing all fifty would be wrong somewhere the day it published. Check with the programme.
- Whether an appeal will succeed. Documentation and step-therapy denials are frequently resolvable; a benefit exclusion is a contract term and rarely is.
The figure that decides a year of treatment. Manufacturer self-pay prices are national.
What changed nationally in the last eighteen months
Three things moved, and none of them was a state policy.
- Manufacturer self-pay channels opened. A cash price of $349 replaced a roughly $1,349 list price as the realistic no-coverage number.
- An approved oral tablet arrived at $149 for starter doses, which changed the cheapest approved route entirely.
- The compounding pathway narrowed when the shortages were declared resolved in February 2025, so the cheapest unapproved route became harder to access.
A page written before those changes gives materially wrong advice today, which is why every figure here carries the date it was read.
A note on how we handle state pages
We do not publish fifty near-identical pages with a state name swapped in. Medicaid policy changes mid-year, and a page claiming to state current coverage for a named state would be wrong somewhere within weeks of publishing. What travels reliably is the structure: which layer decides your price, which layers are national, and the five questions that settle it. That is what this page gives you.
Common questions
Why do I see different prices for the same drug in different states?
Usually you are not seeing a different price for the same thing. Manufacturer self-pay pricing is national and identical everywhere. What differs is coverage — whether a state Medicaid programme covers the obesity indication, and whether your employer bought a benefit that includes weight-loss drugs. Two people in the same city with different employers routinely face completely different costs.
Is a telehealth provider cheaper than a local clinic?
Sometimes, and the comparison is rarely like for like. A telehealth membership frequently sits outside the advertised medication price, and the medication itself may be an approved product or a compounded preparation with no trial of its own. Compare the all-in monthly figure at a maintenance dose, and establish which product you are actually buying.
My plan denied it. Is that final?
It depends entirely on the wording. A denial citing insufficient documentation or step therapy is a clinical question, and dated weight history, coded comorbidities and documented prior attempts frequently resolve it. A denial saying the benefit is excluded from your plan is a contract term your employer chose, and clinical evidence does not address it.
Does the manufacturer savings card work everywhere?
It is national, and it is barred for Medicare and Medicaid beneficiaries by federal law. It also reduces an existing copay rather than acting as a coupon, so it does nothing if your plan does not cover the drug at all — there is no copay to reduce.